ReviewTherapeutics and clinical risk management2016
The role of inflammation in cardiovascular diseases: the predictive value of neutrophil-lymphocyte ratio as a marker in peripheral arterial disease.
Review in Therapeutics and clinical risk management, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04756115 (Impact of Nutritional and Inflammatory Status in Patients With Critical Limb-threatening Ischemia), which is not on this map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Impact of Nutritional and Inflammatory Status in Patients With Critical Limb-threatening Ischemia: a Retrospective Cohort Stud
Who cites it
37 citing papers in PubMed.
- Microbial lysate upregulates host oxytocin.Brain, behavior, and immunity · 2017Trial
- Asthma is associated with atherosclerotic artery changes.PloS one · 2017Trial
- The effect of biologic disease modifying anti-rheumatic drugs on the neutrophil-lymphocyte ratio in psoriatic arthritis patients.Clinical rheumatology · 2026Observational
- Inflammation-modulating agents in chronic limb-threatening ischemia: a narrative review of therapeutic potential and future directions.Annals of medicine and surgery (2012) · 2026Article
- Systemic inflammation markers and the prevalence of osteoporosis and osteopenia: A NHANES cross-sectional study.Journal of family medicine and primary care · 2025Article
- Development and validation of a nomogram for in-stent restenosis within 2 years in patients after iliac or femoral artery stent placement.BMC surgery · 2025Article
- The Role of Admission Glucose and Inflammatory Markers in Histopathological Features of Atherosclerotic Plaques in Carotid and Femoro-Popliteal Arteries.Medicina (Kaunas, Lithuania) · 2025Observational
- Time dependent predictors of cardiac inflammatory adverse events in cancer patients receiving immune checkpoint inhibitors.Cardio-oncology (London, England) · 2025Article
- Current Prognostic Biomarkers for Peripheral Arterial Disease: A Comprehensive Systematic Review of the Literature.Metabolites · 2025Review
- Pro-inflammatory markers as predictors of arterial thrombosis in aged patients with peripheral arterial disease post revascularization.Frontiers in medicine · 2025Article
- Rethinking Mitral Annular Calcification and Its Clinical Significance: From Passive Process to Active Pathology.Journal of personalized medicine · 2024Review
- Reversion of the Inflammatory Markers in Patients With Chronic Limb-Threatening Ischemia.Journal of the American Heart Association · 2024Observational
- Gender differences in the relationship between the systemic immune-inflammation index and all-cause and cardiovascular mortality among adults with hypertension: evidence from NHANES 1999-2018.Frontiers in endocrinology · 2024Article
- Systemic immune-inflammation index (SII) and the risk of all-cause, cardiovascular, and cardio-cerebrovascular mortality in the general population.European journal of medical research · 2023Article
- Comparison of the oxidative profiles before and after revascularization in peripheral arterial disease: a pilot study.Journal of clinical biochemistry and nutrition · 2023Article
- The Role of Neutrophils in Lower Limb Peripheral Artery Disease: State of the Art and Future Perspectives.International journal of molecular sciences · 2023Review
- Effects of bioactive compounds from Pleurotus mushrooms on COVID-19 risk factors associated with the cardiovascular system.Journal of integrative medicine · 2022Review
- Predictive Value of Neutrophil-Lymphocyte Ratio as a Marker in Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Retrospective Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Circulating microRNAs as predictive biomarkers of coronary artery diseases in type 2 diabetes patients.Journal of clinical laboratory analysis · 2022Review
- The Inflammatory Pattern of Chronic Limb-Threatening Ischemia in Muscles: The TNF-α Hypothesis.Biomedicines · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral arterial disease (PAD) is an important manifestation of atherosclerosis, with increasing prevalence worldwide. A growing body of evidence shows that the systemic inflammatory response is closely related to the development, progression, and prognosis of atherosclerosis. In the last decade, several studies have suggested the role of measured inflammatory biomarkers as predictors of severity and prognosis in PAD in an effort to stratify the risk of these patients, to improve treatment selection, and to predict the results after interventions. A simple inflammatory marker, more available than any other, is the neutrophil-lymphocyte ratio (NLR), which can be easily obtained in clinical practice, based on the absolute count of neutrophils and lymphocytes from the differential leukocytes count. Many researchers evaluated vigorously the NLR as a potential prognostic biomarker predicting pathological and survival outcomes in patients with atherosclerosis. In this work, we aim to present the role of NLR as a prognostic marker in patients with PAD through a thorough review of the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.